# A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)

> **NCT04988087** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Sjogren Syndrome
- Mixed Connective Tissue Disease

## Interventions

- **DRUG:** MHV370
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04988087
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-02-07
- **Final completion:** 2023-03-07
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988087, "A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04988087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*